GILD

PropThink: Abbot’s Impressive HCV Data Continues the Trend; Everyone’s Got a Candidate

[ACN Newswire] – By Jake KingDevelopers of potential Hepatitis C (HCV) treatments are among the most-traded in the healthcare industry on Monday, following an announcement from Abbot Laboratories (NYSE:ABT) that a combinations … moreView todays social media effects on GILDView the latest stocks trending across Twitter. Click to view dashboard […]